Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Significant Growth in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 67,400 shares, a growth of 6.3% from the March 15th total of 63,400 shares. Approximately 9.0% of the company’s stock are short sold. Based on an average daily volume of 24,900 shares, the days-to-cover ratio is currently 2.7 days.

Analyst Ratings Changes

Several equities analysts have issued reports on BPTH shares. StockNews.com began coverage on shares of Bio-Path in a report on Tuesday. They issued a “sell” rating on the stock. Roth Mkm boosted their price objective on shares of Bio-Path from $12.00 to $40.00 and gave the company a “buy” rating in a report on Wednesday, March 27th.

Bio-Path Stock Performance

NASDAQ:BPTH opened at $3.23 on Thursday. Bio-Path has a one year low of $2.70 and a one year high of $44.80. The firm has a market cap of $2.20 million, a price-to-earnings ratio of -0.08 and a beta of 0.35. The firm’s fifty day moving average is $5.59 and its two-hundred day moving average is $8.56.

Bio-Path (NASDAQ:BPTH) last posted its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, meeting the consensus estimate of ($5.40). During the same quarter in the previous year, the business earned ($10.60) earnings per share. As a group, equities research analysts predict that Bio-Path will post -18.71 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Bio-Path by 77.5% in the fourth quarter. Vanguard Group Inc. now owns 270,029 shares of the company’s stock worth $125,000 after acquiring an additional 117,914 shares during the period. Walleye Capital LLC acquired a new position in shares of Bio-Path in the third quarter worth about $77,000. Renaissance Technologies LLC acquired a new position in shares of Bio-Path in the second quarter worth about $70,000. Citadel Advisors LLC acquired a new position in shares of Bio-Path during the 3rd quarter worth about $35,000. Finally, Virtu Financial LLC acquired a new position in shares of Bio-Path during the 1st quarter worth about $38,000. Institutional investors and hedge funds own 5.74% of the company’s stock.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.